Verdiva Bio
Last verified 2026-05-14. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $411.0Mattributed |
|---|---|
| Latest round | series-a, $411.0M, 2025-01-09attributed |
| Founded | 2024 |
| Headquarters | London, UK |
| Industry | bio |
| Stage | series-a |
| Website | verdiva.bio |
Verdiva Bio is a UK biotech developing convenient oral cardiometabolic therapies including the once-weekly oral GLP-1 ecnoglutide. Patients with obesity and related cardiometabolic disease are the eventual buyers. The company emerged from stealth in 2025 backed by Forbion and other life-sciences VCs.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-09 | series-a | $411.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $411.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $411.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | verdiva.bio, read 2026-05-14 |
| Description | self-reported | verdiva.bio, read 2026-05-14 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.